SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is capturing attention following the formal incorporation of its DAO in the UAE and strategic partnerships to bolster its Aventus Cloud offerings. The community is buzzing about AVT's enterprise-grade technology, Polkadot integration, and low market capitalization, anticipating a significant breakout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a surge in attention following reports of a strategic partnership with Novo Nordisk to distribute weight-loss drugs, resolving their prior dispute. The market is now actively discussing the potential for a significant short squeeze, fueled by high short interest and the dramatic nature of this unexpected collaboration.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is currently a major focus amid escalating geopolitical tensions with Iran, which have significantly disrupted oil tanker traffic through the critical Strait of Hormuz. The market is keenly watching for whether this signals a prolonged supply squeeze or a temporary "fear premium" that could be quickly reversed by a resolution or market intervention.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI ($FAI) is rapidly gaining attention following a significant price surge, with "great AI news" and the overall enthusiasm for AI crypto driving the conversation. Community members are actively debating its potential for exponential growth against concerns of high volatility, with its presence on the Base network adding to the speculative interest.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is generating buzz due to increasing community confidence in Miplyffa's impending European approval and robust U.S. sales momentum, alongside the strategic appointment of a new CFO seen as a catalyst for enhanced commercialization and potential M&A activity.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amid intense community discussion surrounding the anticipated "Clarity Act," with many believing its passage will establish the token as a vital digital commodity for collateralized payments and drive significant institutional adoption. This bullish outlook, however, is heavily counterbalanced by widespread frustration and skepticism over AMP's persistent downtrend and historical price volatility among long-term holders.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat ($WIF) is trending amidst extreme price volatility and widespread investor frustration, as the community laments persistent dumping and a struggle to maintain gains, despite some expressing optimism for an impending rebound and altcoin rally.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending as investors digest its recent positive earnings, significant debt reduction, and the game-changing acquisition of Valaris, positioning it as a deepwater drilling powerhouse. The community is actively discussing perceived undervaluation and frustration over the stock's current price action, which many feel is disconnected from surging oil prices driven by escalating geopolitical tensions.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as an activist investor's significant stake and a new CEO fuel community debate over a potential turnaround, directly clashing with recent weak guidance, rising oil prices, and broader geopolitical risks impacting the cruise sector.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is a focal point of discussion amid persistent fraud allegations and concerns over its subprime lending practices, with many investors debating the stock's valuation and its seemingly artificial price movements attributed to ongoing market manipulation and options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury.</li><li>Prior Phase 2a results had already shown favorable safety and tolerability, as well as reduced disease progression.</li><li>Stocktwits users speculated that short selling could be the reason behind the stock’s decline.</li></ul>GRI Bio, Inc. (GRI), on Wednesday, announced encouraging new results from its Phase 2a study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease.The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar repair compared with placebo.<h2 class="st-heading-2">Treatment May Support Lung Tissue Regeneration</h2>Crucially, the new data indicate that GRI-0621 may support the regeneration of lung tissue, including the repair of the alveolar basement membrane and the&nbsp;transition of AT2 (Alveolar Type) epithelial cells to AT1, which are key steps in restoring lung function.Prior Phase 2a results had already shown favorable safety and tolerability, reduced disease progression, and improvements in exploratory endpoints, such as forced vital capacity, with twice as many treated patients maintaining lung function compared with standard care.“The data from the Phase 2a study exceed our expectations. The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue,” said Marc Hertz, chief executive officer of GRI Bio.<h2 class="st-heading-2">Short Selling Speculation</h2>However, despite the seemingly positive development, <a href="https://stocktwits.com/symbol/GRI">GRI shares</a> fell 20%. But users remained bullish, despite what many speculated as short selling.<stembedurl>https://stocktwits.com/Tradebub/message/643136568</stembedurl><stembedurl>https://stocktwits.com/Kookoovia/message/643141732</stembedurl>Despite the sharp intra-day decline, retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier. GRI was also among the top trending tickers on the platform.<h2 class="st-heading-2">Reverse Split</h2>Last week, GRI Bio announced a 1-for-28 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.The action became effective after-market hours on January 23, 2026, while trading on an ex-reverse split basis began on Monday. The split reduced outstanding shares from about 15 million to 536,000.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sbux-stock-climbs-7-premarket-after-q1-results/cmyg421R40I">SBUX Stock Jumps 7% Today – US Transactions Grow For The First Time In Two Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened?

The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.

Equity

<ul class="summary-bullets"><li>QOL Medical will buy Evoke for $11 per share, representing a premium of about 140% from the stock’s closing price on Monday.&nbsp;</li><li>The transaction has been approved by the boards of both companies and is expected to close by the end of 2025.</li><li>QOL Medical intends to finance the transaction with cash on hand. &nbsp;</li></ul>Shares of Evoke Pharma, Inc. (EVOK) more than doubled on Tuesday after the company said that it has entered into a definitive agreement to be acquired by privately-held QOL Medical for $11 per share.The purchase price represents a premium of about 140% from the stock’s closing price on Monday.Following the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/04/3180135/28255/en/Evoke-Pharma-Enters-into-Definitive-Agreement-to-Be-Acquired-by-QOL-Medical.html">announcement</a>, <a href="https://stocktwits.com/symbol/EVOK">EVOK shares</a> shot up 134% by Tuesday afternoon to hit $10.72 as of the time of writing, but still remained below the deal price.<h2 class="st-heading-2">Terms Of The Deal</h2>Florida-based QOL Medical will initiate a tender offer to acquire all outstanding shares of Evoke through a subsidiary. Once the tender offer is completed, a unit of QOL Medical will merge with Evoke.&nbsp;The transaction has been approved by the boards of both companies and is expected to close by the end of 2025. QOL Medical intends to finance the transaction with cash on hand.Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a chronic condition where the stomach takes too long to empty due to nerve damage caused by poorly controlled diabetes. Symptoms include nausea, vomiting, and bloating, among others.The gastric delay caused by gastroparesis can compromise absorption of orally administered medications, and until approval of Gimoti, treatment was available only in oral and injectable formulations.“GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions,” QOL Medical CEO Derick Cooper said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EVOK jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/59;" src="data:image/png;base64,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" width="621" height="59" alt="EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the stockholders.<stembedurl>https://stocktwits.com/erb71/message/634823600</stembedurl>EVOK stock is up by 143% this year and by 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

Nasdaq-listed shares of Nyxoah SA (NYXH) soared 13% on Monday morning after the company announced that the first U.S commercial patients with Obstructive Sleep Apnea (OSA) have been successfully implanted with its Genio system.OSA is a common sleep disorder where the upper airway repeatedly collapses during sleep, leading to breathing pauses. It is associated with increased mortality risk and comorbidities, including cardiovascular diseases, depression, and stroke.Nyxoah’s Genio therapy is a mask-free treatment option and works by gently stimulating hypoglossal nerves to contract muscles on both sides of the tongue, keeping the airway open throughout the night. The Genio System features a battery-free stimulator that’s externally powered by a sleep wearable, with customizable settings. It provides an alternative to CPAP therapy, which uses a machine to deliver pressurized air through a mask, keeping the airway open during sleep and preventing breathing pauses.Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee (VAC) approvals, and achieved successful coverage from major payors.“What's also particularly encouraging is the strong demand we're seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.nyxoah.com/press-releases">added</a>.The Genio system received approval from the U.S. Food and Drug Administration in August for a subset of patients with moderate to severe OSA. The approval was supported by a trial that demonstrated Genioi’s efficacy regardless of a patient's sleeping position.<a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> is down by 30% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adobe-expects-us-holiday-online-sales-to-reach-253-4-billion-this-year/ch6R3KNR3gh">Adobe Expects US Holiday Online Sales To Reach $253.4 Billion This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder

Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Deutsche Bank sees 6% upside for EURO STOXX 50 by end of the year

Investing.com -- Deutsche Bank forecasts the Euro Stoxx 50 to rise by 6% by the end of 2025, maintaining its index target unchanged despite ongoing trade tensions.

Trump raises tariff demands in EU trade talks to 15-20% - FT

Investing.com -- U.S. President Donald Trump has increased his demands in trade negotiations with the European Union, now seeking a minimum tariff of 15 to 20 percent in any potential deal, according to a report from the Financial Times, citing people briefed on the discussions.

SPEU
SPDR Portfolio Europe ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SPEU News

SPEUSPDR Portfolio Europe ETF